I. Introduction
===============

Between 1984 and 1995, high-dose chemotherapy (HDC) based mainly on platinum compounds (cisplatin and carboplatin) with autologous bone marrow transplantation or peripheral blood stem cell transplantation were performed with the goal of achieving long-term survival in patients with advanced and refractory epithelial ovarian cancer \[[@B27], [@B28], [@B37], [@B38]\]. This approach was taken based on the results of *in vitro* studies \[[@B2], [@B3]\], in which a higher dose of platinum compounds was shown to be likely to kill more ovarian cancer cells \[[@B15], [@B20], [@B30]\]. However, subsequent studies sugges­ted that the dose of platinum compounds is not necessarily correlated with treatment effects, including a randomized study performed in 1995 by the Gynecologic Oncology Group (GOG) in the U.S. in patients with ovarian cancer at Stage III and IV. In this study, Group A received 8 courses of 50 mg/m^2^ cisplatin (CDDP) and 500 mg/m^2^ cyclophosphamide (CPM), and Group B received 4 courses of 100 mg/m^2^ CDDP and 1000 mg/m^2^ CPM; therefore, the total doses of the two groups were the same. In groups A and B, respectively, the response rates were 60% and 55%, the 4-year survival rates were 20% and 20%, the mean survival times were 19.5 and 21.3 months, and the mean progression-free survival times were 12.1 and 14.3 months. Since there were no significant differences between the patients in the two groups, these results indicate that the dose intensity is not correlated with chemotherapeutic effects \[[@B21]\]. Similar results have been obtained in subsequent randomized studies \[[@B8], [@B14], [@B16]\], and it is now generally thought that doubling the recommended dose does not improve chemotherapeutic effects in a multi-drug regimen including platinum compounds.

II. Combination Chemotherapy with Hematopoietic Stem Cell Transplantation for Advanced Epithelial Ovarian Cancer
================================================================================================================

More than 15 years have passed since the introduction of HDC for advanced epithelial ovarian cancer, and HDC is now performed more safely and effectively due to hematopoietic stem cell support \[[@B24]\]. Therefore, it has become possible to increase the dose intensity in HDC compared with doses used in conventional chemotherapy, leading to expectations of improved progression-free survival (PFS) and overall survival (OS) \[[@B5], [@B12], [@B19], [@B25], [@B26], 39--[@B42]\]. However, the results of randomized studies comparing HDC with conventional chemotherapy show that the complete remission period is short and the long-term survival rate is only 10--20% in HDC, although an apparent high responsiveness and high response rate are observed at the beginning of treatment \[[@B5], [@B25], [@B26], [@B39], [@B41]\]. The conventional regimen in HDC is mainly based on platinum compounds: combined treatment of 100--150 mg/m^2^ CDDP and 800--1600 mg/m^2^ CBDCA (fundamental agents) with CPM, etoposide and thiotepa is generally performed.

We initially performed a pilot study to observe long-term prognosis in 105 patients with advanced and recurrent ovarian cancer, using 1--2 courses of 100--150 mg/m^2^ CDDP, 100 mg/m^2^ adriamycin (ADM) and 1600--2400 mg/m^2^ CPM; or 900--1600 mg/m^2^ CBDCA and 1500--3000 mg/m^2^ CPM. In this study, the respective 5-year PFS and OS rates were 35.7% and 58.1% in Stage III patients, 22.6% and 33.7% in Stage IV patients, and 31.0% and 37.5% in recurrent patients. Furthermore, among 65 Stage III and IV patients, the respective rates of PFS and OS were 51.5% and 74.3% in patients with a residual tumor diameter of not more than 5 mm, 0% and 30.8% in patients with a diameter of 5 mm to 20 mm, and 16.7% and 22.6% in patients with a tumor ­diameter of not less than 20 mm \[[@B37]\].

We recently showed that immunohistochemical expression of mutant p53 protein is decreased by HDC in ovarian cancer tissues, and that the level of p53 immuno-expression is related to the chemotherapeutic effect (Figs. [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) \[[@B11]\]. The p53 tumor suppressor gene is closely associated with DNA repair and apoptosis, and mutant p53 accumulates in tumor cells of advanced refractory ovarian cancer, causing the cells to proliferate. In cancer cells sensitive to platinum-based chemotherapy, wild-type p53 induces apoptosis and repair of damaged DNA, whereas chemotherapy-resistant cancer cells include a mutant p53 that cannot induce apoptosis of cancer cells and does not inhibit cancer cell growth \[[@B36]\]. In advanced refractory ovarian cancer treated with ­platinum-based HDC, most p53 protein-positive tumor cells underwent apoptosis, and p53 expression was suppressed in one tumor that recurred after HDC and was removed in a second reduction surgery \[[@B36]\]. In contrast, p53 protein-positive tumor cell growth was not suppressed in conventional chemotherapy (CONV) using a normal dose of cisplatin, and high p53 expression was found in a tumor that recurred after CONV and was removed in a second reduction surgery \[[@B36]\].

Legros *et al.* performed a pilot HDC study using melphalan (140 mg/m^2^), or CBDCA (400 mg/m^2^ on Days 1--4) and CPM (1600 mg/m^2^ on Days 1--4) in 53 Stage III and IV patients, and found 5-year PFC and OS rates of 23.6% and 59.9%, respectively \[[@B19]\]. Of particular importance, a complete pathological response was confirmed in a second-look operation in 19 of 24 survivors. Furthermore, Ledermann *et al.* (in the European group study) reported that the median OS is 59 months in Stage III patients and 40 months in Stage IV after HDC \[[@B18]\]. All these results indicate a favorable long-term prognosis following use of HDC, compared with conventional chemotherapy.

III. Use of HDC for Recurrent and Refractory Ovarian Cancer at Tokai University Hospital
========================================================================================

HDC combined with autologous stem cell transplantation has been performed for advanced epithelial ovarian ­cancer at our hospital since 1984 \[[@B27], [@B28], [@B37], [@B38]\]. Here, we present a retrospective study of the long-term effects of HDC in patients with recurrent and refractory ovarian cancer who were treated until 1996. The subjects were 20 epithelial ovarian cancer patients in whom the lesion disappeared and remission was attained at initial treatment but recurrence was then observed, in whom a poor response occurred and tumor markers did not become negative after initial treatment, who showed positive laparoscopic findings after initial treatment, or who had no response to initial treatment and are refractory to HDC. In 18 of these 20 patients, we performed a second-look operation before HDC to observe the level of recurrence in the abdominal cavity, and conducted tumor reduction surgery (Fig. [3](#F3){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Six of the 20 patients have survived and 14 have died; the Kaplan-Meier survival curve is shown in Figure [4](#F4){ref-type="fig"}. In 9 patients, tumor reduction surgery resulted in the remaining tumor having a diameter of not more than 5 mm before HDC, and 5 of these 9 patients showed long-term survival. In contrast, in 6 patients the residual tumor diameter was 20 mm or greater, and all of these patients died from 4 to 32 months after HDC treatment (mean survival period: 16 months). These data were partly the basis of the significant difference (p\<0.05) in the survival curves of patients with a residual tumor diameter of 5 mm or greater (n=11) and those with a residual ­diameter of less than 5 mm (n=9) (Fig. [4](#F4){ref-type="fig"}).

A significant difference (p=0.0238) was found in the platinum-free interval (PFI) (duration from previous HDC to second HDC) between the 6 surviving patients (range: 26--44 months, mean: 35.5 months) and the 14 patients who died (range: 4--48 months, mean: 20.1 months) (Fig. [5](#F5){ref-type="fig"}). Also, the 13 recurrent patients who initially showed remission had a higher survival rate (a 5-year survival rate of 53.8%) compared to the 7 refractory cases (a 3-year survival rate of 14.3%) (Table [2](#T2){ref-type="table"}). Concerning the histology of the ovarian cancer, 6 of the 7 refractory cases had clear cell carcinoma or mucinous adenocarcinoma.

After administration of a HDC regimen of 2400 mg/m^2^ CPM, 100 mg/m^2^ ADM and 150 mg/m^2^ CDDP, autologous bone marrow transplantation was performed. In our supportive care protocol, patients with hemoglobin \<8.0 g/dl or platelet levels \<2.0×10^4^/µl were indicated for transfusions of 15Gy-irradiated red blood cells or platelets, respectively. If the patients became febrile, broad-spectrum antibiotics were administered. Intravenous administration of G-CSF con­tinued until confirmation of bone marrow recovery to 1.0×10^4^/µl white blood cells. Peripheral leukocyte count was continuously less than 100/µl for 4 days, and 17 days were required for neutrophils to recover to at least 1500/µl and 13 days for platelets to reach at least 50,000/µl (Table [3](#T3){ref-type="table"}). Fever (not less than 38°C) accompanied by leucopenia was observed for a mean period of 2.5 days. Overall, the results indicated that removal of as much as possible of the tumor is favorable (if possible, the residual tumor diameter should be less than 5 mm) for attainment of high treatment efficacy in HDC for recurrent and refractory ovarian cancer as a ­second-line chemotherapy. In addition, a long PFI from the previous treatment may be beneficial.

IV. New Treatment Strategy
==========================

The history of chemotherapy for ovarian cancer includes the introduction of a platinum compound (cisplatin, CDDP) in 1970, and since then treatment based mainly on this compound has been thought to be most effective \[[@B13], [@B17]\]. However, nephrotoxicity and peripheral nerve disorder are dose-limiting factors in cisplatin therapy, and severe visual disturbance may also occur \[[@B29]\], thereby requiring careful attention to side effects with use of cisplatin. ­Carboplatin (CBDCA), a second-generation platinum compound, was subsequently developed; the anti-tumor effect of CBDCA is almost equal to that of CDDP \[[@B1], [@B7]\], and the potency of CBDCA is 4 times lower than that of CDDP \[[@B32]\]. Furthermore, unlike CDDP, CBDCA induces only very mild nephrotoxicity and peripheral nerve disorder, and its limiting side effect of bone marrow suppression can be ­alleviated by reducing the dose according to the degree of renal dysfunction in individual patients \[[@B6]\].

In the late 1980s, drug tolerance toward platinum compounds was identified as a significant prognostic factor, and expectations were placed on discovery of new anticancer agents. Among these, paclitaxel (PTX) was shown to have no cross-tolerance with platinum compounds, suggesting that it could be a new agent for treatment of ovarian cancer. PTX was approved in the US and Europe in 1992, and the optimal dose of PTX has subsequently been investigated \[[@B4], [@B10], [@B23]\]. Many clinical studies based mainly on PTX have been conducted \[[@B22], [@B33]--[@B35]\], and combination chemotherapy of PTX and CBDCA is now common as the "gold standard" for epithelial ovarian cancer treatment. In Japan, the decision to allow coverage of PTX in the health insurance system from December 1997 has allowed the drug to be used for general treatment of ovarian cancer patients.

In 2004, Japan Society of Gynecologic Oncology issued Ovarian Cancer Treatment Guidelines \[[@B31]\]. The main purposes of these guidelines are to define appropriate treatments for ovarian cancer, to reduce the differences in treatments levels among facilities, and to establish safer and more effective treatments. Combination therapy of PTX and CBDCA may be the optimal regimen for chemotherapy based on the results of many previous studies \[[@B9], [@B22], [@B33]--[@B35]\]; however, when administration of 175--180 mg/m^2^ PTX and AUC5-6 CBDCA was started (every 21--28 days, 6--9 courses) in our facility, approximately 30% of the patients showed strong bone marrow suppression. The decreases of leukocytes and platelets by 2--3 grades sometimes persisted, requiring reduction of the doses of PTX and carboplatin, and consequently decreasing treatment efficacy and quality in some cases. In this context, it is important to note that most data cited in the guidelines \[[@B31]\] were obtained in European and American patients. In particular, optimal doses for Japanese women have not been determined and no recommended treatment has been established for recurrent refractory ovarian cancer, although anticancer agents for salvage chemotherapy are listed in the guidelines. Therefore, we suggest that further randomized studies of treatment for recurrent ovarian cancer be conducted.
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###### 

Characteristics of 20 recurrent and refractory epithelial ovarian cancer patients with HDC who were treated at Tokai University Hospital

  Case   Age   Primary surgery       Secondary surgery   2nd HDC-regimen   No. of courses   Survival time \[months\]   
  ------ ----- ----------------- --- ------------------- ----------------- ---------------- -------------------------- --------
  1\.    56    IV                S                       Micro             CAP              1                          57
  2\.    45    IIIb              S                       Micro             CAP              2                          140
  3\.    29    Ia                M                       \>20              CAP              2                          4^†^
  4\.    47    IIIc              S                       £20               CAP              2                          21^†^
  5\.    48    IIIc              S                       \>20              CAP              2                          32^†^
  6\.    56    IIIc              M                       ---               CAP              2                          156^†^
  7\.    49    IIIc              S                       \>20              CAP              2                          17^†^
  8\.    45    Ic                C                       \>20              CAP+VP16         2                          12^†^
  9\.    52    IIIc              E                       Micro             CBDCA+CPM\*      1                          60
  10\.   46    IIIb              E                       Micro             CBDCA+CPM\*      1                          79
  11\.   43    IIIb              S                       £20               CBDCA+CPM\*      1                          79
  12\.   63    IIIb              S                       Micro             CBDCA+CPM\*      1                          102
  13\.   52    IIIb              S                       Micro             CBDCA+CPM\*      1                          34^†^
  14\.   53    IIIc              S                       Micro             CBDCA+CPM\*      1                          89^†^
  15\.   37    IIc               C                       £20               CBDCA+CPM\*      2                          22^†^
  16\.   38    Ia                M                       5                 CBDCA+CPM\*      2                          12^†^
  17\.   50    IIIc              S                       5                 CBDCA^\#^+VP16   1                          17^†^
  18\.   63    IV                S                       \>20              CBDCA^\#^+VP16   1                          25^†^
  19\.   42    Ic                C                       ---               CBDCA^\#^+VP16   2                          27^†^
  20\.   41    Ic                S                       \>20              CBDCA+VP16+Tes   1                          6^†^

S: serous, M: mucinous, C: clear cell, E: endometrioid.

CAP: cyclophosphamide (CPM) 500--2400 mg/m^2^+adriamycin 50--100 mg/m^2^+cisplatin 100--150 mg/m^2^. VP16: 600--900 mg/m^2^, carboplatin (CBDCA): 750--1500 mg/m^2^, CPM\*: 1500--3000 mg/m^2^, CBDCA^\#^: 600--750 mg/m^2^, Tes: tespamin 600 mg/m^2^, ^†^: dead patients, ---: non secondary surgery.

###### 

Survival after HDC in recurrent and refractory ovarian cancer patients

                              No. of survivors (survival %) after HDC                          
  --------------------------- ----------------------------------------- ----------- ---------- ----------
  Recurrent patients (n=13)   13 (100)                                  10 (76.9)   7 (53.8)   7 (53.8)
  Refractory patients (n=7)   3 (42.9)                                  1 (14.3)    1 (14.3)   1 (14.3)

###### 

Days required for recovery of peripheral blood count after HDC[a](#tblfn1){ref-type="table-fn"} in 20 recurrent and refractory ovarian cancer patients

                                   Median days (range)
  -------------------------------- ------------------------------------------------
  Leukocyte count under 100/µl     4 (0--9)
  Neutrophil count over 500/µl     13.5[b](#tblfn2){ref-type="table-fn"} (10--19)
  Neutrophil count over 1,500/µl   17[b](#tblfn2){ref-type="table-fn"} (11--46)
  Platelet count over 50,000/µl    13[b](#tblfn2){ref-type="table-fn"} (0--21)
  Neutropenic fever up over 38°C   2.5 (0--7)

HDC regimen: cyclophosphmice 2400 mg/m^2^+adriamycin 100 mg/m^2^ +cisplatin 150 mg/m^2^.

Days after autologous bone marrow transplantation.
